Physician profile
Thalia Lopez
NPI 1235624842
$3,943.00
in general payments reported to CMS, 2019-2025
25 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $33.42 · 2021: $63.14 · 2022: $270 · 2023: $773 · 2024: $760 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742 · Consulting Fee: $608 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.78 |
| Consulting Fee | $607.50 |
| Education | $109.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $953.10 | 2025 | Tremfya |
| Abbvie INC. | $844.12 | 2021-2025 | |
| Amgen INC. | $352.20 | 2022-2025 | Krystexxa, Evenity, Tavneos |
| Ucb, INC. | $337.50 | 2023-2025 | Cimzia, Bimzelx |
| Alexion Pharmaceuticals, INC. | $174.79 | 2023-2024 | Strensiq |
| Mallinckrodt Hospital Products INC. | $152.06 | 2025 | Acthar |
| Alvogen INC | $131.43 | 2022-2024 | Teriparatide |
| Aurinia Pharma U.S., INC. | $128.11 | 2022-2025 | Lupkynis |
| Genzyme Corporation | $124.29 | 2022 | |
| Viiv Healthcare Company | $117.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.56 | 2023-2024 | Ofev |
| Novartis Pharmaceuticals Corporation | $88.58 | 2025 | |
| Ani Pharmaceuticals, INC. | $69.09 | 2023 | Purified Cortrophin Gel |
| Radius Health, INC. | $56.54 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.46 | 2023-2025 | Saphnelo |
| Actelion Pharmaceuticals US, INC. | $31.85 | 2023 | Uptravi |
| Alkermes, INC. | $24.87 | 2021 | |
| Kyowa Kirin, INC. | $22.49 | 2024 | Crysvita |
| Depuy Synthes Sales INC. | $19.76 | 2022 | |
| Glaxosmithkline, LLC. | $18.74 | 2020 | |
| Lilly USA, LLC | $17.09 | 2024 | Taltz |
| Fidia Pharma USA INC. | $15.87 | 2025 | Hymovis |
| Merck Sharp & Dohme LLC | $14.68 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thalia Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.